Washington, D.C. — The U.S. administration has announced a new set of agreements with nine pharmaceutical companies to reduce the prices of selected prescription medicines, marking the largest expansion so far of the federal drug pricing initiative under President Donald Trump.
With these latest announcements, most major drugmakers targeted under the administration’s pricing strategy have now entered into voluntary agreements. According to senior officials, only a small number of companies have yet to confirm participation.
The agreements are intended to bring U.S. drug prices closer to those paid in other developed countries. Administration officials said the structure of the new deals is consistent with earlier arrangements and focuses on international price alignment rather than mandated price controls.
While details on individual medicines and specific price reductions were not disclosed, officials emphasized that the combined effect of these agreements is expected to lower costs for patients and federal healthcare programs.
Following the announcement, President Trump indicated that the administration may soon engage with health insurance providers to address insurance-related healthcare costs. Discussions with insurers are expected to take place in the coming weeks.
These potential talks come as enhanced Affordable Care Act subsidies approach expiration, raising concerns about higher premiums for millions of Americans.
Healthcare analysts note that the expanding scope of pricing negotiations reflects a broader effort to improve affordability across the healthcare system, with increasing attention on insurers and other intermediaries that influence patient out-of-pocket expenses.
By
